IndexIQ Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

IndexIQ Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$4.62M	Sell	6,613 -1,278	-16%	-$809K	0.16%	121
2021 Q4	$4.98M	Buy	7,891 +104	+1%	+$63.9K	0.17%	99
2021 Q3	$4.71M	Sell	7,787 -14	-0.2%	-$8.69K	0.16%	107
2021 Q2	$4.36M	Sell	7,801 -95	-1%	-$48.1K	0.15%	108
2021 Q1	$3.74M	Buy	7,896 +6,468	+453%	+$3.15M	0.13%	119
2020 Q4	$690K	Buy	+1,428	New	+$771K	0.03%	287

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IndexIQ Advisors's REGN Position: Q1 2022 in Review

IndexIQ Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q1 2022, selling an estimated $809K and leaving 6,613 shares worth $4.62M. The position accounts for 0.16% of the portfolio, ranked #121.

IndexIQ Advisors first reported a position in REGN in Q4 2020 and has held it in 6 quarters since. The position peaked at $4.98M in Q4 2021. 1,095 funds tracked by Wall St. Rank hold REGN as of Q1 2022.

IndexIQ Advisors held 6,613 shares of Regeneron Pharmaceuticals worth $4.62M as of Q1 2022.
IndexIQ Advisors sold 1,278 Regeneron Pharmaceuticals shares in Q1 2022, an estimated $809K.
Regeneron Pharmaceuticals made up 0.16% of IndexIQ Advisors's portfolio in Q1 2022, its #121 holding.
IndexIQ Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 6 quarters since.
IndexIQ Advisors's Regeneron Pharmaceuticals position peaked at $4.98M in Q4 2021.
1,095 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.